← All trials
NCT04705337
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2021
- Primary completion
- Jun 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Jan 12, 2021
- Last posted
- Jan 12, 2021
- Enrollment
- 350
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medical University of BialystokLead sponsor
- Poznan UniversityOverall official - principal investigator
- Poznan UniversityCollaborator
- University of Campania Luigi VanvitelliCollaborator
- Institute of Cardiology, Warsaw, PolandCollaborator
- Medical University of LodzCollaborator
- John Paul II Hospital, KrakowOverall official - principal investigator
- John Paul II Hospital, KrakowCollaborator
- Nicolaus Copernicus UniversityCollaborator
- Medical University of BialystokStudy chair
- Medical University of LodzOverall official - principal investigator
- Cardinal Stefan Wyszyński Institute of CardiologyOverall official - principal investigator
- University of OpoleOverall official - principal investigator
- University of OpoleCollaborator
- Nicolaus Copernicus UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.